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CONTEXTE :  
Plusieurs études ont identifié une association entre l’Indice de Masse Corporelle 
(IMC) et l’incidence ainsi que la sévérité de la maladie d’Alzheimer (MA), mais 
cette relation n’est actuellement pas encore pleinement comprise. 
OBJECTIFS de l’ETUDE : 
L’objectif primaire de cette étude était d’établir la possible association entre l’IMC 
et les biomarqueurs de la MA dans le liquide céphalo-rachidien (LCR) chez des 
sujets avec et sans troubles cognitifs. L’objectif secondaire de cette étude était 
d’investiguer si l’IMC pouvait contribuer à améliorer la précision d’un modèle 
clinique afin de prédire l’occurrence pathologique des biomarqueurs de la MA dans 
le LCR des patients en consultation de la mémoire souffrant de troubles cognitifs. 
MÉTHODE :  
107 sujets âgés avec des déficits cognitifs (dont 91 patients en consultation de la 
mémoire avec des troubles cognitifs légers [MCI] et 16 patients souffrent d’une 
démence légère de type Alzheimer) et 55 sujets volontaires sains ont été inclus 
dans l’étude. Tous les sujets ont reçu une évaluation clinique et 
neuropsychologique exhaustive ainsi qu’une ponction lombaire afin d’y récolter les 
biomarqueurs de la MA dans le LCR. Des régressions linéaires multiples et des 
analyses ROC ont été menées afin d’établir l’association entre l’IMC et les 
biomarqueurs de la MA dans le LCR.  
RÉSULTATS : 
L’IMC est corrélée positivement avec les taux d’Aβ42 dans le LCR et négativement 
avec tau and P-tau181 chez les participants avec des troubles cognitifs. Ces 
associations sont indépendantes de l’âge, le sexe, le niveau éducatif, le type et la 
sévérité des troubles cognitifs, ces facteurs de risques cérébro-vasculaires et la 
présence de l’allèle APOEε4. De plus, l’IMC a amélioré de façon significative la 
sensibilité et la spécificité d’un modèle multifactoriel prédisant la présence d’un 
profil pathologique des biomarqueurs de la MA dans le LCR. 
CONCLUSION:  
Un faible IMC est associé avec une pathologie cérébrale de la MA plutôt qu’avec un 
trouble cognitif chez des sujets âgés avec un MCI et une démence légère. Avec 
d’autres facteurs cliniques, un IMC en diminution pourrait aider le clinicien à 
identifier des patients avec un trouble cognitif en lien avec la MA. 
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A B S T R A C T
Background: Several studies have identiﬁed an association between body mass index (BMI) and the incidence
and severity of Alzheimer's disease (AD) but this relationship is not fully understood.
Objective: The primary objective of this study was to assess the possible association between BMI and cere-
brospinal ﬂuid (CSF) biomarkers of AD pathology in subjects with normal cognition and cognitive impairment.
The secondary objective was to test whether BMI may contribute to improve the accuracy of a clinical model to
predict AD pathology in memory clinic patients with cognitive impairment.
Method: One hundred and seven elderly subjects with cognitive impairment (91 memory clinic patients with
mild cognitive impairment [MCI] and 16 with dementia of AD type) and 55 cognitively healthy volunteers were
included in this study. All subjects received a comprehensive clinical and neuropsychological evaluation and a
lumbar puncture for CSF biomarker analysis. Multiple linear regressions and receiver operating characteristic
(ROC) analyses were carried out to assess the association between BMI and the CSF biomarkers of AD pathology.
Results: BMI was positively correlated with the CSF levels of Aβ42 and negatively with tau and P-tau181 in
participants with cognitive impairment. The associations were independent of age, sex, educational level, type
and severity of cognitive impairment, cerebrovascular risk factors and the presence of the APOEε4 allele.
Furthermore, BMI signiﬁcantly improved the sensitivity and speciﬁcity of a multi-factorial model to predict the
presence of an AD CSF biomarker proﬁle.
Conclusion: Lower BMI is associated with cerebral AD pathology rather than with cognitive impairment in el-
derly subjects with MCI and mild dementia. Along with other clinical factors, decreasing BMI may help the
clinician to identify patients with cognitive impairment due to AD.
1. Introduction
Alzheimer disease (AD) is the most common cause of dementia in
older age (60–80% of cases) (Prince et al., 2013). The development of
AD is characterized by a long asymptomatic phase followed by a pro-
dromal stage with beginning cognitive decline and mild cognitive im-
pairment (MCI). Cerebral accumulation of amyloid-beta (Aβ) plaques,
neuronal cell death, and aggregation of hyperphosphorylated tau as
neuroﬁbrillary tangles are core features of the AD brain pathology
(Musiek and Holtzman, 2015). The cerebro-spinal ﬂuid (CSF) con-
centrations of Aβ42, tau, and P-tau181 represent well-established bio-
markers of AD and allow for the detection of the disease speciﬁc pa-
thology years before the dementia stage (Scheltens et al., 2016).
The body mass index (BMI) is a clinical measure deﬁned by a per-
son's weight in relation to height. Numerous aﬀections have been as-
sociated with BMI. Regarding the relation of BMI with AD, an apparent
“obesity paradox” has been described, i.e. high BMI is associated with
risk of (AD) dementia during mid-life whereas in late-life there is an
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association between low BMI and clinically diagnosed AD (Fitzpatrick
et al., 2009). More precisely a high BMI in midlife is associated with an
increased risk of developing diabetes, vascular pathology, hypertension
and hypercholesterolemia that are all independent risk factors for de-
veloping cognitive impairment and AD dementia in later life. High BMI
in midlife has been also associated with cerebral metabolic and struc-
tural changes that may early contribute to the development of AD pa-
thology (Erol, 2008). However, in later life, weight loss and low BMI
appear to be associated with severity of cognitive impairment or de-
mentia (Albanese et al., 2013; Luchsinger et al., 2008; Smith et al.,
2014), faster cognitive decline (Deschamps et al., 2002), and with
postoperative delirium (Chung et al., 2015; Juliebo et al., 2009) Fur-
thermore, weight loss may be an early event in cognitive decline, and
may precede the dementia diagnosis (Buchman et al., 2006; Johnson
et al., 2006; Knopman et al., 2007).
While weight loss in older people with cognitive impairment may be
detrimental and increase frailty, the relationships between low BMI and
cognitive decline, and their causes are not well understood. Possible
explanations are that low BMI may result from cognitive impairment
and decline with consequences on nutrition and everyday activities; or
that speciﬁc brain pathology such as AD pathology may result in sys-
temic metabolic changes with consequent weight loss. Evidence sup-
porting this later hypothesis was found in the “Alzheimer's Disease
Neuroimaging Initiative” (ADNI) cohort lower BMI was associated with
CSF biomarkers of AD pathology, in both cognitively normal and im-
paired patients (Ewers et al., 2012; Vidoni et al., 2011). Also, a post
mortem study has found that high amount of cerebral AD pathology is
correlated to low BMI (Buchman et al., 2006).
Diagnosis of AD based on clinical and neuropsychological features
(McKhann et al., 2011) has limited accuracy in discriminating between
cognitive impairment due to AD pathology and cognitive impairment of
other causes (Beach et al., 2012). This is particularly the case in MCI, a
group in which the etiology of cognitive impairment and the prognosis
are very heterogeneous (Winblad). Recently proposed revised criteria
both include the use of biomarkers to increase the diagnostic and pre-
dictive accuracy in patients with dementia; and extend the possible
diagnosis of the disease to the prodromal stage of AD, i.e. to MCI due to
AD (Albert et al., 2011; McKhann et al., 2011). However, biomarkers
are not always available, or their use may be limited by contra-
indications, patient's refusal, and costs. Therefore, the identiﬁcation of
additional clinical factors associated with AD pathology may help to
improve clinical diagnostic accuracy and to identify, among memory
clinic patients, those at high risk of having AD. In this context, BMI, or
BMI variation over time along with other clinical features may con-
tribute to improve early diagnosis and diﬀerential diagnosis of AD.
The aim of this study was to assess the relationships between BMI
and AD CSF biomarkers related to amyloid pathology, neuronal injury,
and tau hyperphosphorylation. In addition, we addressed the question
whether BMI can contribute to improve predictive models of AD pa-
thology in elderly cognitively normal (CN) subjects and in memory
clinic patients with MCI and mild dementia.
2. Material and methods
2.1. Subjects
One hundred and sixty two community-dwelling subjects aged
50 years or older, 55 of them being CN, and 107 memory clinic patients
with cognitive impairment (CI, of which 91 subjects were diagnosed
with MCI and 16 with mild dementia of AD type) were included in a
prospective longitudinal cohort study aiming at investigating clinical
and biological factors associated with AD pathology. The study was
approved by the local ethics committee and informed consent was ob-
tained from all participants.
The study participants with CI were recruited among outpatients
with cognitive impairment referred to the Memory Clinics, Department
of Psychiatry and the Department Clinical Neurosciences, University
Hospital of Lausanne for investigation of their cognitive complaints.
Exclusion criteria were severe concomitant neurological, psychiatric or
somatic comorbidities that could aﬀect cognition. All subjects under-
went a full clinical evaluation, made by senior neurologists, old age
psychiatrists or geriatricians. The clinical examination and the Hospital
Anxiety and Depression Scale were used to assess the presence of re-
levant depression or anxiety symptoms (Zigmond and Snaith, 1983).
Trained neuropsychologists performed a neuropsychological assess-
ment. The neuropsychological assessment included the Mini Mental
State Examination (MMSE), the Buschke Double Memory Test (Buschke
et al., 1997), the digit span forward and backward (Wechsler, 1955),
the Stroop Test (Stroop, 1935), the letter ﬂuency task (Cardebat et al.,
1990), and the Trail Making Tests A and B (Reitan, 1958). The func-
tional assessment included the activities of daily living (ADL) and in-
strumental ADL (IADL) (Lawton and Brody, 1969) as well as the CDR
(Morris, 1993). The clinical examination, the neuropsychological test
battery, ADL and IADL were used to determine the CDR and the CDR-
sum of boxes (−SOB) scores and to verify inclusion and exclusion
criteria. All tests and scales used in this study are validated and widely
used in the ﬁeld. The CI subjects were further divided into three CI
subgroups according to their cognitive proﬁle: amnestic single domain
CI (n = 36), non-amnestic CI (n = 10), or mixed impairments (i.e.
amnestic multidomain; n = 60).
BMI was measured and a standard blood sample was taken on the
day of the lumbar puncture, after overnight fasting.
The diagnosis of MCI or of mild dementia was made by a consensus
conference of senior physicians and neuropsychologists prior to the
inclusion in the study, based upon neuropsychological and clinical
evaluations according to published criteria (McKhann et al., 2011;
Winblad et al., 2004). Patients with a positive diagnosis of MCI or mild
dementia were considered together, as the CI group, in accordance with
revised concepts of AD considering the disease as a biological con-
tinuum of developing cerebral pathology without clear diﬀerences be-
tween MCI and mild dementia (Albert et al., 2011). All the subjects in
the CI group had memory impairment (≥1.5 SD below the means ad-
justed for sex, age and education in the verbal memory tasks of Buschke
Double Memory Test (Buschke et al., 1997)), and/or impairment in
other cognitive domains such as executive tasks or language skills. All
subjects in the CI group also had a Clinical Dementia Rating Scale
(CDR) (Morris, 1993) score of at least 0.5 (subjects with a CDR score of
0.5 were categorized as MCI subjects, and subjects with a CDR score of
1 were categorized as mild dementia subjects).
CN subjects were community dwelling healthy volunteers recruited
by advertisement or among relatives of memory clinic patients. The
clinical and neuropsychological assessment included the same tests
battery and questionnaires as for the CI participants. The CN partici-
pants had no history or evidence of cognitive decline and a CDR score of
0.
2.2. Blood and cerebrospinal ﬂuid collection
Venous and lumbar punctures were performed between 8:30 and
9:30 am after overnight fasting at the recruiting memory centres. For
lumbar puncture, a standardized technique with a 22G “atraumatical”
spinal needle and a sitting or lying position was applied (Popp et al.,
2007). Cerebrospinal ﬂuid (CSF) was collected for analysis using
polypropylene tubes. Routine CSF cell count and protein quantiﬁcation
was performed. Remaining CSF was centrifuged, frozen in aliquots, and
stored at −80 °C until assay.
2.3. CSF biomarker measure and APOE genotyping
Aβ42, tau, and P-tau181 concentrations in the CSF samples were
measured by ELISA, using commercially available assays (Fujirebio,
Gent, Belgium). Biomarker ratios (tau/Aβ42 and P-tau181/Aβ42) as
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markers of concomitant presence of amyloid pathology and tau pa-
thology (Scheltens et al., 2016; Duits et al., 2014) were also calculated.
Diﬀerent approaches have been proposed to deﬁne the AD CSF bio-
marker proﬁle, but there are still no universal cutoﬀs established for
CSF biomarkers (Duits et al., 2014). As there may be signiﬁcant dif-
ferences between centres, it is recommended to deﬁne centre speciﬁc
cutoﬀs which should be conﬁrmed by longitudinal clinical follow-up
evaluations and, ideally, by post-mortem histology (Molinuevo et al.,
2014). Accordingly, we determined the centre cutoﬀ for CSF P-tau181/
Aβ42 (i.e., 0.0779), we conﬁrmed this cutoﬀ value by using longitudinal
clinical follow-up data, and compared it to the literature. Brieﬂy, the
centre cutoﬀ was determined in a previous study using data from
N= 120 subjects (48 healthy volunteers with normal cognition and 72
memory clinic patients with MCI or mild dementia of AD type) as the
value that optimized the Youden index of the Received Operating
Characteristic (ROC) curve of prediction of CDR categories (CDR = 0 vs
CDR > 0; Area Under the Curve [AUC] = 0.789, accuracy: 0.733)
(Popp et al., 2017; Tautvydaite et al., 2017). This cutoﬀ was further
conﬁrmed to be a highly signiﬁcant predictor of cognitive decline (i.e.
change in global cognition as measured by MMSE at a follow-up visit
18 months after inclusion) after considering multiple possible con-
founders (Beta =−0.436; p < 0.00001; unpublished data). The de-
termined cutoﬀ for P-tau181/Aβ42 was similar to values previously
reported by other (Duits et al., 2014).
To evaluate possible interactions and eﬀects of the APOE genotype
on the addressed relationships, leukocyte genomic DNA was isolated
from EDTA blood with the Qiagen blood isolation kit (Qiagen, Hilden,
Germany) and the APOE genotype was determined as previously de-
scribed (Jansen et al., 2015; Popp et al., 2010).
2.4. Follow-up visits
To address the question whether baseline AD CSF biomarker levels
were associated with BMI changes over time, and whether lower BMI at
baseline may indicate a risk of rapid cognitive decline, we used clinical
follow-up data available for a subset of 61 participants, of which 28
were in the CN group and 33 in the CI group. The clinical and neu-
ropsychological follow-up evaluation was performed by the same
methods and tests used at the ﬁrst visit. In some cases, the adminis-
tration full neuropsychological test battery was not possible due to the
participant's cognitive impairment. The MMSE score was available in all
participants and used as a measure of global cognition.
2.5. Statistics
2.5.1. Between-group comparisons
The between-group (CN vs CI) diﬀerences in continuous variables
were assessed using Student's t-test for independent samples and asso-
ciations among categorical variables were analyzed by Pearson's χ2-test
of independence.
2.5.2. Correlations between BMI and AD CSF biomarkers
The strength of the linear association between BMI and AD CSF
biomarkers was assessed using the Pearson linear correlation coeﬃ-
cient. The correlations were performed for the whole population, as
well as for the CN and CI groups separately. The Pearson's correlation
coeﬃcient was also calculated between BMI and the other continuous
variables.
2.5.3. Associations of BMI and AD CSF biomarkers level
In order to evaluate the contribution of BMI in predictive models of
the level of AD CSF biomarkers, multiple linear regressions were used.
All models for predicting Aβ42, tau and P-tau181 (dependent variables)
were adjusted for age, gender, number of education years, severity of
cognitive impairment (MMSE score), presence of ApoEε4 allele and
comorbidities (i.e. history of high blood pressure,
hypercholesterolemia, diabetes, smoking and stroke). In order to de-
termine the best ﬁnal models for each dependent variable, a selection
was performed using a backward elimination approach (conservative
method for choosing the best potential model).
Fundamental assumptions of the regressions (satisfactory normal
distribution and constant variance for residuals) were assessed by gra-
phical means for ﬁnal models. Whenever the ﬁt diagnostics was not
satisfactory, the uncertainty of estimated parameters were evaluated
based on a large number of bootstrap iterations (n = 10,000). Analyses
were performed for the whole population, as well as separately for CN
and CI subjects (referred to as CN and CI groups).
2.5.4. Accuracy of models predicting the AD CSF biomarker proﬁle with
and without BMI
A Binary logistic regression model (Generalized Linear Model with
logit link), integrating age, sex, number of education years, MMSE score
and presence of ApoEε4 allele, was used to predict the AD CSF bio-
marker proﬁle (dichotomous outcome), in CI subjects. After adjusting
this model, the sensitivity and speciﬁcity measurements were per-
formed both with and without inclusion of BMI to measure the pre-
dictive power of BMI on the outcome. The ROC method was used to
compare the accuracy of the two models.
2.5.5. BMI changes in relation to AD CSF biomarkers and cognitive decline
Finally, in order to explore whether the AD CSF biomarkers levels
were associated with BMI changes over time, BMI change from baseline
was included in the multiple linear regression models. This was per-
formed in a subset of 61 participants (28 CN and 33 CI), for which
measures of BMI at follow-up was available. In addition, in order to
assess whether lower BMI at baseline was associated with cognitive
decline, we performed a multivariate regression analysis with MMSE
score decline as the dependent variable and including BMI, age, sex,
ApoEε4 status and CSF AD proﬁle as predictor variables (these pre-
dictors were selected using the backward elimination approach).
For all analyses, α≤ 0.05 was accepted as nominal level of sig-
niﬁcance; all statistical analyses were performed using SPSS 23 for
Windows software.
3. Results
3.1. Subjects' characteristics
Subjects' characteristics are shown in Table 1. The CI and CN groups
did not diﬀer for sex, number of education years, BMI, history of ar-
terial hypertension, stroke and smoking, but they diﬀered for age,
MMSE score, CDR score, history of diabetes, history of hypercholes-
terolemia and the presence of the ApoEε4 allele. The level of the three
investigated AD CSF biomarkers and the AD CSF proﬁle were also
signiﬁcantly diﬀerent in the two study groups (Table 1).
3.2. Correlations between BMI and AD CSF biomarkers
Regarding the whole population, the correlation coeﬃcients (ρ)
between BMI and the AD CSF biomarkers were signiﬁcant. Indeed, BMI
was positively correlated with Aβ42 (ρ= 0.250; p-value≤ 0.001), and
negatively associated with tau (ρ=−0.260; p-value≤ 0.001) and P-
tau181 (ρ=−0.221; p-value≤ 0.01). Correlation coeﬃcients for the
CN and CI groups are shown in Table 2, and graphically represented in
Figs. 1, 2 and 3. In the CI group, BMI was positively correlated with
Aβ42 and negatively correlated with tau, P-tau181 and both biomarkers
ratios: tau/Aβ42 and P-tau181/Aβ42. Correlations within the CI group
appeared to be stronger than for the whole population. By contrast,
none of the correlations were statistically signiﬁcant in the CN group.
BMI was not correlated either with age, hypercholesterolemia,
number of education years, gender, MMSE, CDR, CDR-SOB, or with the
presence of an ApoEε4 allele. History of high blood pressure was
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surprisingly associated with low BMI but subsequent analyses were
made in order to clarify if history of high blood pressure could be a
confounding factor; consequent results demonstrated that it was not
correlated with CSF biomarkers or any other factor.
3.3. Associations of BMI with AD CSF biomarkers level
The backward elimination approach showed that comorbidities
were not signiﬁcant predictors in any of the models, and therefore,
these factors were not included in the ﬁnal models (results for these
predictors are not shown). The regression coeﬃcients β for the other
selected predictors and their associated signiﬁcance levels are pre-
sented in Table 3, for both the CN and CI groups.
Multiple linear regression models conﬁrmed the Pearson's associa-
tions between BMI and 2 of the 3 AD CSF biomarkers: Aβ42 (β= 0.24,
p < 0.01) and tau (β=−0.27, p < 0.01). Ptau-181 was negatively
correlated with BMI but not signiﬁcantly in this model (β=−0.19,
p = 0.055). When considering the CI subgroups (single domain am-
nestic CI, non-amnestic CI and mixed CI), the eﬀect of BMI reached
signiﬁcance in the amnestic CI (n = 36; β= 0.46, p < 0.01) and
mixed CI (n = 60; β= 0.36, p < 0.01) subgroups, but not in the non-
amnestic CI group (n = 10; β= 0.46, p = 0.886). Although the MMSE
score was used to adjust linear regression models, using CDR-SOB
instead of the MMSE score did not change the associations and their
corresponding directions and magnitudes (results not shown).
3.4. Accuracy of models predicting the AD CSF biomarker proﬁle with and
without BMI
ROC analyses predicting pathological AD CSF biomarker proﬁle
using CI group showed 84.62% and 83.61% sensitivity and speciﬁcity,
respectively (Fig. 4). In these analyses, by excluding the BMI from the
model and comparing the result with the model using BMI, we observed
that BMI accounted for a sensitivity and speciﬁcity improvement of
14.85% and 13.84%, respectively (Fig. 4). When performed separately
in the subgroup with MCI, the ROC analysis showed a sensitivity of
88.64% and a speciﬁcity of 78.05% after inclusion of BMI. Adding BMI
accounted for a sensitivity and speciﬁcity improvement of 11.37% and
8.02%, respectively.
3.5. BMI as a predictor of cognitive decline and BMI changes in relation to
AD CSF biomarkers
Regarding the analysis in the subset of 61 subjects with measures of
BMI at follow-up (mean [± SD] follow-up time was 18.5 [± 6.5]
months), higher tau and P-tau181 levels at baseline were signiﬁcantly
associated with decreasing BMI from baseline after controlling for time
to follow-up visit (β=−0.361; p < 0.01 and β=−0.336;
p < 0.01, respectively). Four out of the 33 subjects with MCI transi-
tioned to mild dementia between baseline and follow-up. BMI change at
follow-up was correlated with changes in MMSE score (Spearman cor-
relation: r = 0.578; p < 0.0005) in the CI group.
4. Discussion
We found BMI to be positively associated with cerebral amyloid
pathology and negatively associated with tau hyperphosphorylation
and neuronal injury as measured by CSF biomarkers in the subjects with
CI. The associations remained signiﬁcant after controlling for several
possible confounders. Moreover, including BMI in a multivariate model
substantially improved the classiﬁcation of participants with CI
Table 1
Subjects' characteristics.
CN (n = 55) CI (n = 107) p-Value (CN vs CI) Subgroup with follow-up visits
Measure, unit
Gender (f/m), n 37/18 59/48 n.s.a 38/23
Type of CI (amnestic/non-amnestic/mixed), n – 36/10/60 – 13/2/18
Mean age (SD), years 66.8 (7.9) 73.9 (6.6) < 0.001b 69.5 (7.7)
Mean education years (SD), n 12.8 (2.6) 12.1 (2.7) n.s.b 12.8 (2.8)
Mean MMSE (SD), points 28.5 (1.6) 25.5 (3.5) < 0.001b 27.3 (2.6)
Mean CDR-SOB (SD), points 0 (0) 2.1 (2.2) < 0.001b 0.8 (1.7)
Mean BMI (SD), kg/m2 25.1 (4.3) 25.4 (4.6) n.s.b 25.7 (4.8)
HBP (yes/no), n 14/41 32/57 n.s.a 20/40c
Diabetes (yes/no), n 1/53c 12/88 < 0.05a 3/58
Hypercholesterolemia (yes/no), n 9/43c 27/48 < 0.01a 21/40
History of stroke (yes/no), n 2/53 4/99c n.s.a 2/58c
History of smoking (yes/no), n 30/25 38/57c n.s.a 33/27c
ApoEε4 gene (non-carrier/carrier), n 46/8c 57/43c < 0.001a 41/17c
CSF biomarkers, unit
Mean Aβ42 level (SD), ng/l 968.5 (213.3) 759.5 (348.2) < 0.001b 855.4 (284.4)
Mean hTau level (SD), ng/l 268.4 (187.2) 501.5 (348.2) < 0.001b 396.5 (303.4)
Mean P-tau181 level (SD), ng/l 51.3 (21.2) 73.2 (40.1) < 0.001b 65.0 (43.7)
CSF AD proﬁle (y/n), n 5/50 60/47 < 0.001a 20/40c
CN: Cognitively Normal control subjects; CI: Cognitive Impairment subjects; MMSE: Mini-Mental State Examination; CDR-SOB: Clinical Dementia Rating – Sum of Boxes; BMI: Body Mass
Index; HBP: history of high blood pressure; CSF AD: Cerebrospinal ﬂuid AD proﬁle; SD: standard deviation.
n = number of subjects; n.s.: nonsigniﬁcant.
a Pearson χ2 test.
b t-Test.
c Data is missing for one or more subjects.
Table 2
Correlations between BMI and CSF AD biomarkers for cognitively normal and cognitively
impaired subjects.
Pearson correlation coeﬃcient ρ for CN (n = 55) CI (n = 107)
BMI vs Aβ42 0.131 (n.s.) 0.335⁎⁎⁎
BMI vs tau −0.137 (n.s.) −0.338⁎⁎⁎
BMI vs P-tau181 −0.167 (n.s.) −0.268⁎⁎
BMI vs tau/Aβ42 ratio −0.180 (n.s.) −0.330⁎⁎
BMI vs P-tau181/Aβ42 −0.210 (n.s.) −0.319⁎⁎
Note. CN: Cognitively Normal control subjects; CI: Cognitive Impaired subjects; BMI: Body
Mass Index;
n = number of subjects; n.s.: nonsigniﬁcant.
⁎⁎ p≤ 0.01.
⁎⁎⁎ p≤ 0.001.
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according to the presence of an AD CSF biomarker proﬁle. Preliminary
analyses of longitudinal data in a subsample showed BMI decrease over
time in relation to CSF tau and P-tau181, and in association with cog-
nitive decline.
Weight change in clinically diagnosed AD dementia has been de-
scribed previously and associations between weight loss and disease
severity and progression have been reported (White et al., 1996; Soto
et al., 2012). General physical frailty (low weight, physical fatigue,
sarcopenia, lower gait speed and overall muscular strength) in AD could
result from the progressive loss of cognitive function with consequences
on nutrition and everyday activities. Furthermore, neuropsychiatric
symptoms such as apathy and depression can aﬀect food intake and are
often precursors of cognitive decline (Donovan et al., 2014; Geda et al.,
2014). However, impairment of the general nutritional status is mainly
observed in the more advanced stages of AD dementia (Marino et al.,
2015).
While weight loss in AD may be relate to cognitive and functional
impairment as well as psychiatric symptoms, all with possible con-
sequences on nutrition, another possible explanation is that the devel-
opment of cerebral AD pathology directly aﬀects the organism's
Fig. 1. Scatterplot showing CSF Aβ42 (pg/ml) versus Body Mass Index
(kg/m2) for cognitively normal (CN) and cognitively impaired (CI)
patients.
Fig. 2. Scatterplot showing CSF tau (pg/ml) versus Body Mass Index
(kg/m2) for cognitively normal (CN) and cognitively impaired (CI)
patients.
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metabolism. One of the early neuropathological changes in AD is the
degeneration of the medial temporal lobe cortex (Duara et al., 2008).
This area of the brain may also be related to weight loss (Grundman
et al., 1996). The medial temporal lobe, the entorhinal cortex, and the
hypothalamus host structures involved in the regulation of appetite and
energy metabolism (Ishii and Iadecola, 2015; Val-Laillet et al., 2015).
Alterations in the synthesis and metabolism of glucose have been de-
scribed in AD, and may be explained by pathological changes in these
brain structures (González-Domínguez et al., 2015; Sato and Morishita,
2015). Also, misfolded and aggregated amyloid proteins trigger im-
mune responses at systemic and CNS levels that may signiﬁcantly alter
food intake and overall metabolism as with other known chronic in-
ﬂammatory states (Heneka et al., 2015). Inﬂammation, along with
other pathological processes related to AD, may increase the suscept-
ibility to developing delirium (Popp, 2013), and lower BMI has been
found to be associated with increased risk of delirium in the elderly
(Chung et al., 2015; Oh et al., 2015).
While the association between clinically diagnosed AD dementia
and low BMI has been reported in several publications, only a few
studies have addressed the possible associations between cerebral AD
pathology and BMI, or BMI changes over time. A post mortem autopsy
study found levels of cerebral AD pathology to be associated with BMI
proximate to death, but other pathologies such as Lewy body pathology
and cerebral infarctions were not associated with BMI (Buchman et al.,
2006). Intriguingly, in living older subjects, a study including partici-
pants with subjective memory impairment and MCI found high BMI in
association with higher amounts of ﬁbrillar insoluble protein ag-
gregates as measured by PET (Merrill et al., 2016). Using more speciﬁc
amyloid imaging by PET, another study found low BMI to be associated
with greater cortical amyloid burden in cognitively normal older sub-
jects (Hsu et al., 2016). To our knowledge, the relationships between
BMI and CSF biomarkers of AD pathology have been investigated and
speciﬁcally addressed in only one cohort (ADNI) by two diﬀerent
groups (Ewers et al., 2012; Vidoni et al., 2011), and no longitudinal
results have been published so far. In line with the results from the
ADNI cohort, our results in a more heterogeneous group of participants
Fig. 3. Scatterplot showing CSF P-tau181 (pg/ml) versus Body Mass
Index (kg/m2) for cognitively normal (CN) and cognitively impaired
(CI) patients.
Table 3
Standardized regression coeﬃcients β for selected predictors calculated from multiple linear regression analyses, for cognitively normal and cognitively impaired subjects.
CN (n = 55) CI (n = 107)
Dependent variable Aβ42 tau P-tau181 Aβ42 tau P-tau181
Predictors
BMI n/a −0.25 (p = 0.067) n/a 0.24⁎⁎ −0.27⁎⁎ −0.19 (p = 0.055)
Gender n/a −0.36⁎⁎ n/a n/a n/a n/a
Age n/a n/a 0.27⁎ n/a n/a n/a
NYE n/a −0.26 (p = 0.59) n/a n/a n/a n/a
MMSE score n/a n/a n/a 0.17 (p = 0.061) −0.19⁎ −0.26⁎⁎
Presence of the ApoEε4 allele −0.29⁎ n/a −0.26 (p = 0.058) −0.39⁎⁎⁎ 0.20⁎ 0.23⁎
Note. Predictor variables used in the multiple linear regression models were selected using the backward elimination approach. CN: Cognitively Normal subjects; CI: Cognitively Impaired
subjects; BMI: Body Mass Index; MMSE: Mini Mental State Examination; n = number of subjects; n/a: not applicable, the predictor variable was eliminated from the model by the
backward elimination approach; n.s.: nonsigniﬁcant; NYE: number of years of education.
⁎ p≤ 0.05.
⁎⁎ p≤ 0.01.
⁎⁎⁎ p≤ 0.00.
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including diﬀerent clinical types of MCI suggest that amyloid pa-
thology, neuronal injury, and tau hyperphorsphorylation as measured
by CSF biomarkers are associated with low BMI. These associations
become evident at the pre-dementia clinical stage of AD and seem to be
independent of the severity of cognitive impairment. Moreover, we
found that tau and P-tau levels at inclusion were related to decreasing
BMI over a follow-up time of 18 months suggesting a close and speciﬁc
relationship between cerebral tau-related neurodegeneration and
weight loss.
Memory clinic patients presenting MCI and mild dementia are a
very heterogeneous group regarding the underlying pathology
(Winblad et al., 2004). Only a part of these subjects have cerebral AD
pathology as the main cause of cognitive impairment. Diﬀerentiating
MCI due to AD from MCI due to other conditions may have major
consequences for clinical decision making, especially regarding further,
individually chosen diagnostic tests or a “watchful waiting” attitude
and clinical follow-up, and early and speciﬁc treatment options (Popp
and Arlt, 2011). Biomarkers of AD pathology are not always available,
or their use may be limited by contraindications, patient refusal, and
costs. Therefore, it remains important to identify clinical factors that
improve the accuracy of the AD diagnosis. Despite being an easily
available and low-cost measure, BMI, or change in BMI over time, is not
yet integrated in the clinician's rationale as an indicator of AD pa-
thology in patients with cognitive complaints or beginning decline. To
our knowledge, this is the ﬁrst study that evaluated the potential of BMI
to improve, together with other clinical factors, the diagnostic accuracy
of AD. Adding BMI to a model including demographic and clinical
factors substantially improved sensitivity and speciﬁcity of the model to
predict the presence of AD pathology in memory clinic patients with
MCI or mild dementia. The results suggest that BMI could be considered
along with other relevant clinical parameters to evaluate the individual
risk of the presence of cerebral AD pathology in patients with cognitive
impairment, in particular if biomarkers are not easily available.
Analysis using longitudinal follow-up data available in a subgroup
of the study participants showed a correlation between decreasing BMI
and MMSE score decline. While preliminary, this additional ﬁnding are
in line with a recent study showing that in patients with MCI lower BMI
predicts evolution to dementia (Cova et al., 2016), and suggests that
decreasing BMI may not only be a clinical indicator of cerebral pa-
thology, but also a clinical factor that could help to identify patients at
risk for rapid cognitive decline.
The current study has limitations. As a measure of the nutritional
status, BMI was shown to have equal or superior performance compared
to other body fat-measuring methods (Smith et al., 2014). More precise
assessment of changes in body composition may provide additional and
more speciﬁc information, however (Buﬀa et al., 2014; Cova et al.,
2017). Furthermore, the CN group was too small to appropriately ad-
dress the question of whether the observed associations between BMI
and AD CSF biomarkers may precede the clinical stage of the disease.
While preliminary analysis in a subset of subjects with follow-up data
indicates that cerebral tau pathology is associated with decreasing BMI
over time, further prospective investigation in a larger sample is needed
to understand the dynamics between weight loss and cerebral pa-
thology.
5. Conclusions
While the precise mechanisms underlying the association between
weight loss, metabolic changes, and AD remain to be unraveled, our
study provide new evidence suggesting that low and decreasing BMI is
associated with CSF biomarkers of cerebral AD pathology in memory
clinic patients with MCI or mild dementia. When considered together
with other clinical features, decreasing BMI may contribute to improve
the diagnosis of AD at early clinical stages, and may indicate higher risk
of rapid cognitive decline.
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